DS Healthcare Group, Inc. (DSKX) appointed Dr. Brijeshkumar Patel, PhD to the newly created position of director of research and development. In this role Dr. Patel will focus on the development of transdermal drug delivery systems for the Company's hair-care products, as well as restructuring existing and new molecules for increased absorption and effectiveness. He will work alongside a team of chemists both within DS Healthcare and with the company's external consultants to develop skin-care applications.
In addition to maintaining the highest quality controls for the company's over-the-counter formulations, Dr. Patel will also collaborate with Aptiv Solutions, DS Healthcare's clinical research organization (CRO) on the company's prescription-grade hair formulation currently under development.
"We are executing on the pursuit of science that enhances hair regrowth and youthful skin. Dr. Patel joins us as Director of R&D to lead our clinical development efforts for both our prescription hair loss development program and our portfolio of over-the-counter hair care and skin care products," stated DS Healthcare President and CEO Daniel Khesin. "We've seen demand for our over-the-counter products continue to grow based on the performance of our proprietary, patent-pending formulations. With Dr. Patel on our team, we believe we will be in a position to accelerate our innovation and clinical programs with a goal towards expanding our intellectual property, product portfolio and corresponding revenues."
Dr. Patel has over seven years of research experience in developing novel drug delivery systems for pulmonary, oral and topical delivery of small molecules and peptide drugs. He brings to DS Healthcare specific expertise in designing preclinical and clinical study protocols. He has authored 10 articles published in peer-reviewed scientific publications and delivered over a dozen poster and oral presentations at scientific conferences.
In other news, DS Healthcare Group recently announced its intention to file an Investigational New Drug application with the U.S. Food and Drug Administration for a topical hair loss treatment. If approved, it would be the third FDA-approved treatment for hair loss and only the second topical treatment. The company has recently filed two patents for its prescription and over-the-counter hair loss formulations.